NEW ORAL ANTICOAGULANTS (LITERATURE REVIEW)


Cite item

Full Text

Abstract

Anticoagulant are one of the most commonly used drugs in various fields of clinical medicine. These include tools that affect hemostasis and are used to prevent or treat arterial or venous thrombosis and tromboèmbolism. The knowledge of their properties and the skills of their therapeutic application are necessary to achieve the maximum benefits and limit the frequency of bleeding complications. This overview focuses on the practical use of some new anticoagulants, including oral medicines which have been recently introduced into clinical practice as well as those which are in various stages of clinical trials.

References

  1. Last JA. The Missing Link: The Story of Karl Paul Link. Toxicol Sci 2002;66:4-6.
  2. Whitlon DS, Sadowski JA, Suttie JW. Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition. Biochemistry 1978;17:1371-77.
  3. Kristiansen C, Lassen JF, Dahler-Eriksen BS, et al. Evaluation of a simple dosage scheme for transition from phenprocoumon to warfarin in oral anticoagulation. Thromb Res 2000;98:157-63.
  4. van Geest-Daalderop JH, Pequeriaux NC, van den Besselaar AM. Variability of INR in patients on stable long-term treatment with phenprocoumon and acenocoumarol and implications for analytical quality requirements. Thromb Haemost 2009;102:588-92.
  5. Stehle S, Kirchheiner J, Lazar A, et al. Pharmacogenetics of oral anticoagulants: a basis for dose individualization. Clin Pharmacokinet 2008;47:565-94.
  6. Perez-Andreu V, Roldan V, Anton AI, et al. Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. Blood 2009;113:4977-79.
  7. Klein TE, Altman RB, Eriksson N, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009;360:753-64.
  8. Agnelli G, Eriksson BI, Cohen AT, et al. Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran. Thromb Res 2009;123:488-97.
  9. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008;47:285-95.
  10. Stangier J, Stahle H, Rathgen K, et al. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. J Clin Pharmacol 2008;48:1411-19.
  11. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007;370:949-56.
  12. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007;5:2178-85.
  13. Ginsberg JS, Davidson BL, Comp PC, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009;24:1-9.
  14. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2009;361:1139-51.
  15. Diener H-C, Connolly S, Ezekowitz MD, et al. Dabigatran Compared to Warfarin in Patients with Atrial Fibrillation and Prior TIA or Stroke: Results of RE-LY American Stroke Association International Stroke Conference 2010 - Late Braking Science 2010; Abstract 195.
  16. Healey JS, Eikelboom J, Wallentin L, et al. Effect of age and renal function on the risks of stroke and major bleeding with dabigatran compared to warfarin: An analysis from the RE-LY study. J Am Coll Cardiol 2010;55:1078-120.
  17. Koti MJ, Parekh A, Connolly SJ, et al. Dabigatran versus warfarin in patients with atrial fibrillation - An analysis of patients undergoing cardioversion. J Am Coll Cardiol 2010;55:1078-124.
  18. Oldgren J, Alings M, Darius H, et al. Dabigatran versus warfarin in atrial fibrillation patients with low, moderate and high CHADS2 score: A RE-LY subgroup analysis. J Am Coll Cardiol 2010;55:0903-0904.
  19. Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost 2009; epub ahead of print.
  20. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism. N Engl J Med 2009;361:2342-52.
  21. Oldgren J, Budaj A, Granger C, et al. Randomised dabigatran etexilate dose finding study in patients with acute coronary syndromes post index event with additional risk factors for cardiovascular complications also receiving aspirin and clopidogrel (RE-DEEM). Circulation 2009;120:2160-2161. Abstract 165.
  22. Perzborn E, Strassburger J, Wilmen A, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor. J Thromb Haemost 2005;3:514-21.
  23. Kubitza D, Becka M, Wensing G, et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 an oral, direct Factor Xa inhibitor - after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005;61:873-880.
  24. Kubitza D, Becka M, Zuehlsdorf M, et al. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol 2006;46:549-58.
  25. Kubitza D, Becka M, Roth A, et al. Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin 2008;24:2757-65.
  26. Haas S. Rivaroxaban - an oral, direct Factor Xa inhibitor: lessons from a broad clinical study programme. Eur J Haematol 2009;82:339-49.
  27. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008;358:2765-75.
  28. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008;372:31-39.
  29. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008;358:2776-86.
  30. Turpie AG, Bauer KA, Davidson B, et al. Once-Daily Oral Rivaroxaban Compared with Subcutaneous Enoxaparin Every 12 Hours for Thromboprophylaxis after Total Knee Replacement: RECORD4. ASH Annual Meeting Abstracts 2008. Blood 2008;112:abstr. 35.
  31. Gibson C, Mega J, Hammett C, et al. Randomized Comparison of Rivaroxaban, an Oral Direct Factor Xa Inhibitor, with Placebo in Patients with Acute Coronary Syndromes: The ATLAS ACS-TIMI 46 Trial. Circulation 2008;118:2311.
  32. Buller HR. Once-Daily Oral Rivaroxaban Versus Placebo in the Long-Term Prevention of Recurrent Symptomatic Venous Thromboembolism. the Einstein-Extension Study. ASH Annual Meeting Abstracts 2009. Blood 2009;114:LBA-Abstract 2.
  33. Lu G, DeGuzman FR, Lakhotia S, et al. Recombinant Antidote for Reversal of Anticoagulation by Factor Xa Inhibitors. ASH Annual Meeting Abstracts 2008. Blood 2008;112:abstr. 983.
  34. Chan MY, Cohen MG, Dyke CK, et al. Phase 1b randomized study of antidotecontrolled modulation of factor IXa activity in patients with stable coronary artery disease. Circulation 2008;117:2865-74.
  35. Veyrat-Follet C, Vivier N, Trellu M, et al. The pharmacokinetics of idraparinux, a long-acting indirect factor Xa inhibitor: population pharmacokinetic analysis from Phase III clinical trials. J Thromb Haemost 2009;7:559-65.
  36. Trellu M, Perez Y, Ortiz J, et al. Bioequipotency of idraparinux and biotinylated idraparinux after single dose in healthy subjects. J Thromb Haemost 2007;5(Suppl. 2):T-678.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies